You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Tumor-Specific T Cells

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC Trial in Munich (Bone marrow aspiration from the iliac crest, Illinois bone marrow aspiration neddle)

Active, not recruiting
  • Non-small Cell Lung Cancer
  • Bone marrow aspiration from the iliac crest
  • Illinois bone marrow aspiration neddle
  • Munich, Germany
    Division of Thoracic Surgery, Technical University of Munich, Mu
May 16, 2022

Liver Cell Carcinoma Trial in Houston (CATCH T cells, Cytoxan, Fludara)

Recruiting
  • Liver Cell Carcinoma
  • +7 more
  • CATCH T cells
  • +2 more
  • Houston, Texas
    Houston Methodist Hospital
Dec 19, 2022

CNS Tumors, Atypical Teratoid/Rhabdoid Tumor, Diffuse Midline Glioma, H3 K27M-Mutant Trial in Memphis (B7-H3-CAR T cells)

Not yet recruiting
  • Central Nervous System Neoplasms
  • +6 more
  • B7-H3-CAR T cells
  • Memphis, Tennessee
    St. Jude Children's Research Hospital
Apr 18, 2023

Acute Myeloid Leukemia, Myelodysplastic Syndrome Trial in Houston (MultiTAA-specific T cells)

Recruiting
  • Acute Myeloid Leukemia
  • Myelodysplastic Syndrome
  • MultiTAA-specific T cells
  • Houston, Texas
  • +1 more
May 31, 2022

Solid Tumor Trial in Shenzhen (bi-4SCAR GD2/PSMA T cells)

Recruiting
  • Solid Tumor
  • bi-4SCAR GD2/PSMA T cells
  • Shenzhen, Guangdong, China
    Shenzhen Geno-immune Medical Institute
Jun 25, 2022

Advanced Solid Tumor Trial in Beijing (YK0901 cells)

Not yet recruiting
  • Advanced Solid Tumor
  • YK0901 cells
  • Beijing, China
    Department of GI Oncology, Peking University Cancer Hospital
Jun 27, 2023

Advanced Solid Tumor Trial in Dallas (TCRT-ESO-A2)

Withdrawn
  • Advanced Solid Tumor
  • TCRT-ESO-A2
  • (no location specified)
Aug 31, 2022

Brain Tumor, Recurrent, Brain Tumor, Refractory Trial in Houston (HER2-specific T cells)

Recruiting
  • Brain Tumor, Recurrent
  • Brain Tumor, Refractory
  • HER2-specific T cells
  • Houston, Texas
  • +1 more
May 3, 2022

Hodgkin Disease, Non-Hodgkin Lymphoma, Severe Chronic Active Epstein Barr Virus Trial in Houston (MABEL CTLs, Cyclophosphamide,

Recruiting
  • Hodgkin Disease
  • +5 more
  • MABEL CTLs
  • +2 more
  • Houston, Texas
  • +1 more
Jan 13, 2023

Solid Tumor Trial in Guangzhou (tumor-specific TCR-T cells, Interleukin-2)

Recruiting
  • Solid Tumor
  • Guangzhou, Gaungdong, China
    Sun Yat-sen University Cancer Center
Oct 21, 2021

Ependymoma, Glioblastoma, Medulloblastoma Trial in Duarte (IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR

Recruiting
  • Ependymoma
  • +3 more
  • IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes
  • Duarte, California
    City of Hope Medical Center
Mar 9, 2022

Pediatric Solid Tumor, Osteosarcoma, Rhabdomyosarcoma Trial in Memphis (Fludarabine, Cyclophosphamide, MESNA)

Recruiting
  • Pediatric Solid Tumor
  • +15 more
  • Memphis, Tennessee
    St. Jude Children's Research Hospital
Jun 30, 2022

Liver Cancer, Rhabdomyosarcoma, Malignant Rhabdoid Tumor Trial in Houston (CARE T cells, Cytoxan, Fludara)

Not yet recruiting
  • Liver Cancer
  • +5 more
  • CARE T cells
  • +2 more
  • Houston, Texas
    Texas Children's Hospital
Dec 1, 2021

Malignant Epithelial Tumors Trial in Portland (TCR-transduced T cells, CDX-1140, Pembrolizumab)

Not yet recruiting
  • Malignant Epithelial Neoplasms
  • TCR-transduced T cells
  • +2 more
  • Portland, Oregon
    Providence Portland Medical Center
Apr 22, 2022

Advanced Solid Tumor Trial in Chengdu (Dual-targeting CLDN18.2 and PD-L1 CAR-T cells)

Not yet recruiting
  • Advanced Solid Tumor
  • Dual-targeting CLDN18.2 and PD-L1 CAR-T cells
  • Chengdu, Sichuan, China
    West China Hospital, Sichuan University
Oct 9, 2023

Epithelial Ovarian Cancer, Ovarian Carcinoma Trial in Nijmegen (XP-DC vaccinations)

Not yet recruiting
  • Epithelial Ovarian Cancer
  • Ovarian Carcinoma
  • XP-DC vaccinations
  • Nijmegen, Gelderland, Netherlands
    Radboud University Medical Center
Mar 6, 2023

HLA Typing and Tumor Neoantigen Identification forPhase I/II

Recruiting
  • Ovarian Cancer
  • +5 more
    • Houston, Texas
      MD Anderson Cancer Center
    Jul 27, 2022

    HNSCC, Melanoma, Gynecologic Cancer Trial in Portland (DP CD8 TIL, DP CD8 TIL KD, Low dose IL-2)

    Recruiting
    • HNSCC
    • +5 more
    • DP CD8 TIL
    • +2 more
    • Portland, Oregon
      Providence Portland Medical Center
    Jun 5, 2023

    Leukemia, Lymphoblastic (Acute) Trial in Houston (MultiTAA-specific T cells)

    Active, not recruiting
    • Leukemia, Lymphoblastic (Acute)
    • MultiTAA-specific T cells
    • Houston, Texas
    • +1 more
    Aug 6, 2021

    COL6A3 Positive, HLA-A*0201 Positive Cells Present, PRAME Positive Trial in Houston (biological, drug, procedure)

    Active, not recruiting
    • COL6A3 Positive
    • +3 more
    • Aldesleukin
    • +4 more
    • Houston, Texas
      M D Anderson Cancer Center
    Sep 22, 2022

    Pancreatic Cancer Trial in Houston (multiTAA specific T cells)

    Active, not recruiting
    • Pancreatic Cancer
    • multiTAA specific T cells
    • Houston, Texas
    • +2 more
    Feb 7, 2022

    Diffuse Intrinsic Pontine Glioma, High Grade Glioma, Embryonal Tumor Trial in Houston ((C7R)-GD2.CART cells, Cyclophosphamide,

    Recruiting
    • Diffuse Intrinsic Pontine Glioma
    • +3 more
    • (C7R)-GD2.CART cells
    • +2 more
    • Houston, Texas
      Texas Children's Hospital
    Feb 7, 2022

    Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma Trial in Salt Lake City (TAA-T cells, Nivolumab)

    Recruiting
    • Hodgkin Lymphoma
    • Diffuse Large B Cell Lymphoma
    • Salt Lake City, Utah
    • +1 more
    Jul 14, 2021

    Bladder Cancer, Head and Neck Squamous Cell Carcinoma, Cancer of the Salivary Gland Trial in Houston (CAdVEC)

    Recruiting
    • Bladder Cancer
    • +9 more
    • CAdVEC
    • Houston, Texas
      Baylor St. Luke's Medical Center
    Feb 17, 2022

    HLA-A*0201 Positive Cells Present, NY-ESO-1 Positive Tumor Cells Present, Recurrent Myxoid Liposarcoma Trial in Houston

    Active, not recruiting
    • HLA-A*0201 Positive Cells Present
    • +3 more
    • Aldesleukin
    • +3 more
    • Houston, Texas
      M D Anderson Cancer Center
    Feb 25, 2022